Leukemia stem cells (LSCs) are thought to play a central role in the pathogenesis of acute leukemia and likely contribute to both disease initiation and relapse. Therefore, identification of agents that target LSCs is an important consideration for the development of new therapies. To this end, we have previously demonstrated that the naturally-occurring compound parthenolide (PTL) can induce death of human LSCs in vitro, while sparing normal hematopoietic cells. However, PTL has relatively poor pharmacological properties that limit its potential clinical use. Consequently, we generated a family of PTL analogs designed to improve solubility and bioavailability.
Introduction
Recent studies have demonstrated that myeloid and certain forms of lymphoid leukemia arise from malignant stem cells (termed leukemia stem cells, LSCs). [1] [2] [3] LSCs are typically found in a quiescent state and are thus unlikely to respond to standard chemotherapeutic agents which preferentially eradicate actively cycling cells. [4] [5] [6] [7] Indeed, the persistence of LSCs following chemotherapy may be a major factor contributing to clinical relapse. 8, 9 In addition, conventional leukemia therapy is also substantially toxic to normal hematopoietic cells and frequently results in severe myelosuppression.
Therefore, given the drug refractory nature of LSCs, and the importance of normal hematopoiesis, identification of less toxic and more specific forms of therapy are important priorities for the development of better therapeutic regimens.
As a foundation for developing more selective leukemia treatments, our previous experiments have investigated basic properties of primitive AML cells. These studies showed that LSCs from different AML subtypes share characteristics 10 which are unique to AML and thus represent potential therapeutic targets for the selective ablation of LSCs relative to their normal counterparts. 11, 12 Specifically, we reported that NF-κB, a known regulator of growth and survival, is constitutively active in LSCs but not in normal hematopoietic stem cells (HSCs). 13 Notably, many traditional cancer therapies induce activation of NF-κB, a potentially undesirable characteristic likely to facilitate survival of malignant cells. 14, 15 Given the ability of many cancer cells to evade apoptosis, we hypothesized that NF-κB inhibition could be used to facilitate LSC-selective cell death, a concept supported by studies using the proteasome inhibitor MG-132 (known to inhibit NF-κB) with the anthracycline Idarubicin (IDR). 16 However, molecular genetic approaches demonstrated that NF-κB inhibition alone is not sufficient to strongly induce AML-specific apoptosis. Further investigation of pathways induced by MG-132 + IDR treatment revealed activation of p53 and increased oxidative load as prevalent components of the AML cell death process. 7 Collectively, these data suggest that the mechanism of LSC death involves combined inhibition of survival pathways and activation of tumor suppressor and/or stress pathways. 17 More recently, we have shown that robust apoptosis of primary AML cells can be achieved with a single agent, the plant derived compound parthenolide (PTL), which is known to induce oxidative stress and inhibit NF-κB. 7 Importantly, PTL also effectively eradicates AML stem and progenitor cells in vitro while sparing normal hematopoietic cells. Hence, PTL has the ability to eradicate AML stem cells, as well as to ablate bulk leukemia blast cells;
properties that should make this compound an attractive agent for clinical evaluation.
However, despite the utility of PTL determined by in vitro studies, it's solubility is relatively poor, making pharmacological use of the compound difficult. 
DMAPT synthesis and pharmacology
DMAPT was prepared from the reaction of parthenolide with dimethylamine, and the resulting dimethylamino analog was then converted to its water-soluble fumarate salt. Fluorescence was observed using a 100x objective, further magnified by a 2x zoom, on a Leica inverted scanning confocal microscope.
Flow Cytometry
Apoptosis assays were performed as described. 13 Briefly, after 18-24h of treatment, normal and AML specimens were stained for the surface antibodies CD38- 
Canine studies
In vitro and in vivo studies were performed with owner's consent on three animals with a diagnosis of CD34-positive acute leukemia. Case study I -the subject was an 8 year old male Labrador retriever. At the initiation of treatment the animal was in advanced stages of disease and received anti-inflammatory agents, sedatives, diuretics, antibiotics, and prokinetic agents as needed during the course of DMAPT treatments.
In addition, the dog received 40 mg of Prednisone starting at day 5, reduced to 20 mg on day 11 and Mesna 500 mg (3 x day) starting on day 8. At day 14 the animal succumbed to multiple symptoms associated with advanced disease. Case study II -the subject was an 8 year old male mixed breed dog. At the beginning of treatment the WBC was highly elevated (81K/ul) and the animal was receiving Deramaxx 100mg SID.
At day 15, the animal also began receiving Clavamox and Prednisone. At day 24 the animal was withdrawn from study and euthanized at the owner's request due to concern there was not sufficient likelihood of cure to warrant continued treatment. Case study III -the subject was a 12 year old male Pug. Prior to the beginning of DMAPT treatment the WBC was 96.5K/µl and the animal was receiving Predisone (5mg), Famotidine, Clavamox and Hydrocodone. At day 14 the animal was withdrawn from study and euthanized at the owner's request due to concern there was not sufficient likelihood of cure to warrant continued treatment.
U937 differentiation assay
U937 cells were plated at 400,000 cells/ml and treated with DMAPT (2.5µM or 5µM) or 5µM ATRA. Cells were counted and analyzed 72 hours after treatment for expression of CD 11b and viability (DAPI).
Statistical analysis
Statistical analyses and graphs were performed using GraphPad Prism software (GraphPad Software, San Diego, CA). For statistical analysis the data was log transformed and analyzed by one-way ANOVA followed by Tukey post-hoc test. For 2 group comparisons, significance was determined by two-tailed t-tests.
Results

DMAPT selectively eradicates primitive leukemia cells
DMAPT was prepared from the reaction of PTL with dimethylamine, and the resulting dimethylamino analog was then converted to its water-soluble fumarate salt (Neelakantan et al., manuscript in preparation). Initially, we performed detailed biological studies to determine the efficiency and specificity of anti-leukemia properties
for DMAPT. Figure 1A shows that 24-hour exposure of primary human AML cells to either 7.5 µM PTL or DMAPT results in similar mean viability in total and CD34+ cell populations (25% vs. 24%, and 12% vs. 12% respectively, n=25 for PTL and n=39 for DMAPT Figure 1C and 1D show the effect of DMAPT on phenotypically described B-ALL stem/progenitor cells (CD34+CD10-) 3 and CML stem/progenitor cells (CD34+CD38-). 4 These experiments indicate DMAPT also has utility for lymphoid and chronic myeloid forms of leukemia. Finally, to verify the specificity of DMAPT for malignant cells, viability of normal hematopoietic cells was determined. Supplemental   table 3 shows the percent viability for normal mononuclear cells obtained from healthy donors after treatment with either PTL or DMAPT. The data in Figure 1E demonstrate that DMAPT does not significantly affect viability of normal CD34+ or CD34+CD38-hematopoietic cells obtained from healthy donors (n=8; p >0.05). Indeed, the mean viability at 5µM DMAPT was 96% for CD34+ cells and 88% for CD34+CD38-cells. At 7.5µM, the mean viability for both CD34+ and CD34+CD38-populations was over 79%.
Together, the data demonstrate that DMAPT not only induces rapid cell death in phenotypically described AML, CML and ALL stem/progenitor cells, but is also well tolerated by normal stem and progenitor cells.
Functional assays demonstrate that DMAPT ablates primary human AML stem and progenitor cells
In vitro colony assays and NOD/SCID xenotransplant experiments were used to determine whether DMAPT targets functionally defined leukemia progenitor and stem 
DMAPT treatment induces stress responses, inhibits NF-κB, and activates p53
We have previously shown that induction of oxidative stress, inhibition of NF-κB, and activation of p53 are functions associated with anti-LSC activity in primary AML cells. 
DMAPT Pharmacology
To further characterize the potential utility of DMAPT, preliminary pharmacological studies were performed. Not surprisingly, substantial pharmacokinetic (PK) differences were observed in rodent and canine studies. In mice, an oral DMAPT dose of 100mg/kg achieved a Cmax of 25 µM and a half-life (T 1/2 ) of 0.63 hours in serum. In contrast, canine studies showed a Cmax of 61 μM, with a T 1/2 of 1.9 hours when DMAPT was dosed at 100 mg/kg p.o. For both the mouse and canine models, oral bioavailability was approximately 70% in comparison to intravenous administration.
These characteristics represent a significant improvement over PTL, which demonstrated a maximum serum concentration of 200 nM in mice when dosed at 40 mg/kg, which is the highest dose attainable given the relative insolubility of PTL. 18 Furthermore, in preliminary toxicology studies, daily administration of 100 mg/kg DMAPT to mice for 10 consecutive days was well tolerated with no evidence of acute toxicity or changes in hematologic parameters. Similarly, daily oral dosing of dogs at 50-100 mg/kg for 14 consecutive days was well tolerated. Collectively, these studies indicate that the pharmacological properties of DMAPT are superior to PTL.
In vivo biological activity of DMAPT in a murine model
Increased oxidative stress and inhibition of NF-κB are consistent in vitro features of DMAPT treatment (Figure 3 panels A, B and C). Thus, we tested whether such responses were also evident in vivo where they could serve as potential biomarkers for DMAPT activity. To this end, we injected primary human AML cells into sub-lethally irradiated NOD/SCID mice to establish xenografts. At 6 weeks post-injection (a time at which the AML cells have strongly engrafted in bone marrow), mice were treated with a single oral dose of 100mg/kg DMAPT. One hour post-treatment, animals were sacrificed to evaluate the bioactivity of DMAPT in human AML cells isolated from the bone marrow. Figure 3D shows that the NF-κB p65 subunit (yellow) is localized to the cytoplasm upon drug treatment (nucleus shown in blue), an activity indicating substantial inhibition of NF-κB (n=3). In addition, figure 3E shows that Nrf2 (green) localized to the nucleus, indicating its typical activation in response to oxidative stress (n=3). Together, these data indicate that DMAPT induces both the activation of stress responses and inhibition of NF-κB in vivo, and that both of these measurements can be used as biomarkers to monitor drug activity.
In vivo biological activity of DMAPT in spontaneous canine leukemias
Spontaneous leukemias are well documented in dogs, and thus provide a large animal system in which to investigate drug activities. In addition, as mentioned above, the pharmacology observed for DMAPT was notably better in dogs than in mice. Therefore, we employed studies of primary canine leukemia as a means to further characterize the activity of DMAPT. First, in vitro studies were conducted to examine whether NF-κB is constitutively active in canine leukemias and whether such cells are sensitive to DMAPT. Constitutive NF-κB activity (as measured by EMSA) was evident in 7 out of 8 specimens tested (supplemental figure 2A) . Further, in vitro exposure to DMAPT for 24 hours resulted in decreased NF-κB activity (supplemental figure 2C) as well as decreased cell survival (36% mean viability at 10µM, n=6)(supplemental figure 2B). suggesting that the canine LSCs were significantly impaired by the drug in vivo.
Finally, to examine in vivo biomarkers of DMAPT activity, the levels of γH2AX 22 and the NF-κB p65 subunit were analyzed in cells from specimens before and after treatment.
As shown in Figure 5D , increased γH2AX and decreased nuclear NF-κB p65 were detected post-treatment, indicating that DMAPT induced oxidative stress and inhibited NF-κB in vivo.
Discussion
In vivo targeting of LSCs represents a formidable challenge to the leukemia research field. Not only must future therapies more effectively eradicate LSCs, they must do so with less collateral damage to normal tissues. Several biological features of normal stem cells are retained in malignant populations and likely contribute to the difficulty in targeting the LSC population. For example, a mostly quiescent cell cycle status, expression of xenobiotic efflux pumps, and a protective microenvironmental niche are all factors that may shield LSC from therapeutic insult. 23 Thus, these parameters and possibly other aspects of in vivo biology must be considered for the development of improved regimens.
From basic studies of primary human tissue we have previously proposed that two types of events are necessary to induce preferential induction of cell death in LSCs: (i)
inhibition of survival signals (such as NF-κB) and (ii) activation of stress responses. 17 Importantly, neither of these events alone appears to mediate substantial killing of LSC. 16 We hypothesize that stress responses such as increased activity of heat shock proteins, DNA damage pathways, and oxidative stress response factors (i.e. HO-1 and Nrf2), are a direct result of drug-induced cellular damage and that increased NF-κB is a protective reaction to the insult. Thus, by inhibiting elements of the NF-κB pathway (or similar survival factors) the detrimental effects of stress, such as increased oxidative load, are uncovered by regimens that mediate both effects. We further hypothesize the PTL-based drugs fall into this class of drug, in which both induction of stress and inhibition of survival signals are central to the therapeutic mechanism.
In the present report, we have enhanced the anti-leukemia features of PTL, by creating a more pharmacologically useful form of the drug, DMAPT; and demonstrating that the Importantly, functional assays demonstrated that DMAPT specifically ablated primitive human leukemia cells without impairing their normal counterparts. Together, these data indicate DMAPT is a novel therapeutic candidate for targeting human LSCs, and may have utility against a broad range of hematologic cancers.
The findings above provide a strong rationale for taking DMAPT forward to human clinical trials for leukemia. However, we were cognizant that further characterization of the drug in some type of preclinical in vivo model could also be of value. While numerous studies have employed human-mouse xenografts to study biological properties of stem cells in vivo, there has been almost no use of such systems for therapeutic modeling. Indeed, the metabolic differences between mouse and human physiology make pharmacological comparisons difficult. Thus, our human-mouse xenograft experiments were limited to relatively simple single-dose pharmacodynamic studies. In order to derive data more pertinent to human disease, we extended our in vivo studies to include analysis of spontaneous acute leukemia in dogs. While the analysis of canine disease is attractive because it provides a unique means to investigate authentic leukemia in a large animal system, it is also challenging due to the advanced stage in which disease is typically detected. Nonetheless, we were able to conduct three case studies, roughly equivalent to human phase I clinical trials, in which pilot feasibility and pharmacodynamic analyses were performed (Figures 4-5 Top panels show cells stained for NF-κB p65 (yellow) and ToPro3 (blue). Bottom panels show γH2AX (green) and ToPro3 (red).
